Nancy Jean Cox to Azathioprine
This is a "connection" page, showing publications Nancy Jean Cox has written about Azathioprine.
Connection Strength
1.313
-
Association between genetically predicted expression of TPMT and azathioprine adverse events. BMC Pharmacol Toxicol. 2026 Feb 07; 27(1).
Score: 0.224
-
RAB19, SERPINB9P1, and Pancreatitis in Patients Taking Azathioprine in Routine Clinical Practice: Genome and Transcriptome-Wide Association Studies. Clin Pharmacol Ther. 2025 10; 118(4):946-953.
Score: 0.216
-
PTPN2 and Leukopenia in Individuals With Normal TPMT and NUDT15 Metabolizer Status Taking Azathioprine. Clin Transl Sci. 2025 06; 18(6):e70220.
Score: 0.214
-
Race, Genotype, and Azathioprine Discontinuation : A Cohort Study. Ann Intern Med. 2022 08; 175(8):1092-1099.
Score: 0.174
-
Predicted expression of genes involved in the thiopurine metabolic pathway and azathioprine discontinuation due to myelotoxicity. Clin Transl Sci. 2022 04; 15(4):859-865.
Score: 0.170
-
TPMT and NUDT15 Variants Predict Discontinuation of Azathioprine for Myelotoxicity in Patients with Inflammatory Disease: Real-World Clinical Results. Clin Pharmacol Ther. 2022 01; 111(1):263-271.
Score: 0.166
-
Combining clinical and candidate gene data into a risk score for azathioprine-associated leukopenia in routine clinical practice. Pharmacogenomics J. 2020 10; 20(5):736-745.
Score: 0.148